title: [Preliminary analysis on the treatment of ventilator-associated pneumonia caused by pandrug-resistant Acinetobacter baumannii].
abstract: OBJECTIVE
  To analyze the clinical features of pandrug-resistant Acinetobacter baumannii (PDR-Ab) in the Chinese PLA General Hospital and compare the efficacies of different antibiotic treatments in aged patients with ventilator-associative pneumonia (VAP) caused by PDR-Ab.
  
  
  METHODS
  Data were collected from all isolated PDR-Ab strains in our hospital from April 2009 to April 2010. The clinical features, treatment, and outcomes were retrospectively reviewed.
  
  
  RESULTS
  PDR-Ab was found to be the dominant pathogen in 42 of 126 aged VAP patients. Cefoperazone/sulbactam plus minocycline showed good efficacy in 20 patients with PDR-Ab VAP, showing a clinical cure rate of 65% (13/20) and a bacterial eradication rate of 40% (8/20). Another 22 patients were treated with other antimicrobial drugs, achieving a clinical cure rate of 22.7% (5/22) and a bacterial eradication rate of 13.6% (3/22). The factors influencing bacterial clearance were prolonged length of hospital stay and mechanical ventilation prior to positive culture (all P<0.01).
  
  
  CONCLUSIONS
  Cefoperazone/sulbactam plus minocycline can be an effective treatment for VAP caused by PDR-Ab.
authors.affiliation: Department of Respiratory Medicine,Chinese PLA General Hospital,Beijing 100853,China.
authors.forename: Li-wan
authors.initials: LW
authors.lastname: Wang
authors.affiliation: Department of Respiratory Medicine,Chinese PLA General Hospital,Beijing 100853,China.
authors.forename: Lin
authors.initials: L
authors.lastname: Zou
authors.affiliation: Department of Respiratory Medicine,Chinese PLA General Hospital,Beijing 100853,China.
authors.forename: Hong-xia
authors.initials: HX
authors.lastname: Li
authors.affiliation: Department of Respiratory Medicine,Chinese PLA General Hospital,Beijing 100853,China.
authors.forename: Tian-zhi
authors.initials: TZ
authors.lastname: Li
mesh_terms: D040981:Acinetobacter baumannii; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D002438:Cefoperazone / Q000627:therapeutic use*; D024901:Drug Resistance, Multiple, Bacterial; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008911:Minocycline / Q000627:therapeutic use; D053717:Pneumonia, Ventilator-Associated / Q000188:drug therapy* / Q000382:microbiology*; D012189:Retrospective Studies; D013407:Sulbactam / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D002438:Cefoperazone; D008911:Minocycline; D013407:Sulbactam